TY - JOUR
T1 - Vascular and metabolic effects of omega-3 fatty acids combined with fenofibrate in patients with hypertriglyceridemia
AU - Koh, Kwang Kon
AU - Oh, Pyung Chun
AU - Sakuma, Ichiro
AU - Lee, Yonghee
AU - Han, Seung Hwan
AU - Shin, Eak Kyun
N1 - Publisher Copyright:
© 2016 Elsevier Ireland Ltd
PY - 2016/10/15
Y1 - 2016/10/15
N2 - Background Effects of omega-3 fatty acids (n − 3 FA) combined with fenofibrate are not yet investigated, compared with fenofibrate. Methods This was a randomized, single-blind, placebo-controlled, parallel study. Age, sex, and body mass index were matched among groups. All patients were recommended to maintain a low fat diet. Fifty patients with hypertriglyceridemia in each group were given placebo, n − 3 FA 2 g + fenofibrate 160 mg (combination), or fenofibrate 160 mg, respectively daily for 2 months. Results Placebo, combination, and fenofibrate significantly decreased triglycerides by 7%, 41% and 30%, respectively and triglycerides/HDL cholesterol ratio by 11%, 45% and 32%, respectively relative to baseline measurements (all P < 0.05 by paired t-test). When compared with placebo and fenofibrate, these with combination were significant (P < 0.001 by ANOVA). When compared with placebo, both combination and fenofibrate significantly decreased apolipoprotein B and non-HDL cholesterol and improved flow-mediated dilation and reduced CRP and fibrinogen (all P < 0.05 by ANOVA), however, there were no significant differences between combination and fenofibrate. When compared with placebo, both combination and fenofibrate significantly reduced insulin and glucose (both P < 0.05 by ANOVA), and improved insulin sensitivity (P = 0.005 by ANOVA). However, there were no significant differences between combination and fenofibrate. Conclusions When compared with fenofibrate, combination significantly decreased triglycerides and triglycerides/HDL cholesterol ratio. Otherwise, combination and fenofibrate significantly reduced apolipoprotein B and non-HDL cholesterol and improved flow-mediated dilation and reduced CRP and fibrinogen to a similar extent. Also, combination and fenofibrate significantly improved insulin sensitivity to a similar extent by reducing insulin and glucose in patients with hypertriglyceridemia.
AB - Background Effects of omega-3 fatty acids (n − 3 FA) combined with fenofibrate are not yet investigated, compared with fenofibrate. Methods This was a randomized, single-blind, placebo-controlled, parallel study. Age, sex, and body mass index were matched among groups. All patients were recommended to maintain a low fat diet. Fifty patients with hypertriglyceridemia in each group were given placebo, n − 3 FA 2 g + fenofibrate 160 mg (combination), or fenofibrate 160 mg, respectively daily for 2 months. Results Placebo, combination, and fenofibrate significantly decreased triglycerides by 7%, 41% and 30%, respectively and triglycerides/HDL cholesterol ratio by 11%, 45% and 32%, respectively relative to baseline measurements (all P < 0.05 by paired t-test). When compared with placebo and fenofibrate, these with combination were significant (P < 0.001 by ANOVA). When compared with placebo, both combination and fenofibrate significantly decreased apolipoprotein B and non-HDL cholesterol and improved flow-mediated dilation and reduced CRP and fibrinogen (all P < 0.05 by ANOVA), however, there were no significant differences between combination and fenofibrate. When compared with placebo, both combination and fenofibrate significantly reduced insulin and glucose (both P < 0.05 by ANOVA), and improved insulin sensitivity (P = 0.005 by ANOVA). However, there were no significant differences between combination and fenofibrate. Conclusions When compared with fenofibrate, combination significantly decreased triglycerides and triglycerides/HDL cholesterol ratio. Otherwise, combination and fenofibrate significantly reduced apolipoprotein B and non-HDL cholesterol and improved flow-mediated dilation and reduced CRP and fibrinogen to a similar extent. Also, combination and fenofibrate significantly improved insulin sensitivity to a similar extent by reducing insulin and glucose in patients with hypertriglyceridemia.
KW - Fenofibrate
KW - Hypertriglyceridemia
KW - Insulin resistance
KW - Omega-3 fatty acids
UR - http://www.scopus.com/inward/record.url?scp=84978796163&partnerID=8YFLogxK
U2 - 10.1016/j.ijcard.2016.07.038
DO - 10.1016/j.ijcard.2016.07.038
M3 - Article
C2 - 27424313
AN - SCOPUS:84978796163
SN - 0167-5273
VL - 221
SP - 342
EP - 346
JO - International Journal of Cardiology
JF - International Journal of Cardiology
ER -